Ronald Ryder, DO
Cardiovascular Disease · Hamilton, NJNPI 1154309532
Payments from drug & device makers
Across 527 payments — averaging $172.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$63K
- Johnson & Johnson$13K
- Bayer$7K
- Esperion Therapeutics, Inc.$2K
- Kowa Pharmaceuticals America, Inc.$1K
- Amgen$626
- plus $4K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 55 | $63,286 |
| Johnson & Johnson | 87 | $13,030 |
| Bayer | 18 | $7,112 |
| Esperion Therapeutics, Inc. | 3 | $1,647 |
| Kowa Pharmaceuticals America, Inc. | 89 | $1,398 |
| Amgen | 42 | $626 |
| Pfizer | 40 | $519 |
| Boston Scientific | 26 | $478 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $329 |
| Novartis | 50 | $328 |
| AstraZeneca | 16 | $224 |
| E.r. Squibb & Sons, L.L.C. | 13 | $178 |
| Novo Nordisk | 10 | $176 |
| Merck | 10 | $145 |
| Alnylam Pharmaceuticals Inc. | 8 | $119 |
| Kestra Medical Technology Services, Inc. | 3 | $113 |
| Regeneron Healthcare Solutions, Inc. | 6 | $102 |
| Scpharmaceuticals Inc. | 5 | $102 |
| United Therapeutics Corporation | 4 | $98 |
| Actelion Pharmaceuticals US, Inc. | 6 | $96 |
| Altathera Pharmaceuticals LLC | 4 | $95 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $69 |
| Bridgebio Pharma, Inc. | 4 | $67 |
| Arbor Pharmaceuticals, Inc. | 4 | $61 |
| Philips North America LLC | 2 | $58 |
| Daiichi Sankyo Inc. | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Medicure Pharma Inc. | 1 | $23 |
| Atricure, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| CMP Pharma, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$90,670 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Hamilton
- Edward WingfieldHamilton$125K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.